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ABSTRACT
Background and significance Intellectual disability
is a condition characterized by significant limitations in
cognitive abilities and social/behavioral adaptive skills
and is an important reason for pediatric, neurologic, and
genetic referrals. Approximately 10% of protein-encoding
genes on the X chromosome are implicated in
intellectual disability, and the corresponding intellectual
disability is termed X-linked ID (XLID). Although few
mutations and a small number of families have been
identified and XLID is rare, collectively the impact of
XLID is significant because patients usually are unable to
fully participate in society.
Objective To reveal the molecular mechanisms of
various intellectual disabilities and to suggest small
molecules which by binding to the malfunctioning
protein can reduce unwanted effects.
Methods Using various in silico methods we reveal the
molecular mechanism of XLID in cases involving proteins
with known 3D structure. The 3D structures were used
to predict the effect of disease-causing missense
mutations on the folding free energy, conformational
dynamics, hydrogen bond network and, if appropriate,
protein-protein binding free energy.
Results It is shown that the vast majority of XLID
mutation sites are outside the active pocket and are
accessible from the water phase, thus providing the
opportunity to alter their effect by binding appropriate
small molecules in the vicinity of the mutation site.
Conclusions This observation is used to demonstrate,
computationally and experimentally, that a particular
condition, Snyder-Robinson syndrome caused by the
G56S spermine synthase mutation, might be ameliorated
by small molecule binding.
BACKGROUND AND SIGNIFICANCE
It is known that missense mutations cause many
human diseases and underlie the natural differences
between individuals by affecting the structure, func-
tion, interactions, and other properties of expressed
proteins. In some cases, one altered allele can cause
a major health problem. These diseases are usually
rare but serious. Other conditions, such as heart
disease and cancer, are genetically complex, with
alleles from several genes contributing to the dis-
order. The ability to predict whether a given mis-
sense mutation causes disease or is harmless would
be very important for early detection in patients
with a high risk of developing a particular illness.
More useful would be the ability to offer a specific
treatment to reduce or completely eliminate the
effects of disease-causing missense mutations. This
work focuses on further understanding the molecu-
lar mechanisms of various intellectual disabilities
(rare X-linked conditions) and on developing the
methodology and in silico tools for altering their
phenotype by binding small molecules to the corre-
sponding proteins.
Over the past few years, significant progress has
been made in building databases of disease-causing
missense mutations1–4 and sequentially using these
classified mutations for the early identification of
patients at risk.5–8 However, very little work has
been done to develop possible treatments, perhaps
due to a lack of understanding of the pathogenesis
of the effects caused by the mutations.9 10 Another
possible reason is that the common approach in
drug discovery is to design competitive inhibitors
that alter the effect of the disease.11–15 However,
such an approach may not be successful in design-
ing drugs capable of reversing the effects of disease-
causing mutations because most of these effects
cannot be fixed by simply inhibiting a particular
reaction. Instead, drug design should be preceded
by a detailed investigation of the effects caused by
the mutation, followed by analysis to determine
which effects result in disease, and lastly, by a
search for small molecules that can restore the wild
type (WT) function of the corresponding protein
by binding to it.
Rare diseases are particularly promising targets for
exploring the possibility of reversing the effects of
disease-causing missense mutations. First, the fact
that a particular disease is typically caused by a single
mutation makes analysis of the effects much easier as
compared to a complex disease, and thus reduces the
ambiguity of in silico modeling. Second, the observa-
tion that different mutations within the same gene
result in the same phenotype suggests that these
mutations have similar effects on the target protein’s
function and its interactions, thus provides the
opportunity for in silico modeling to identify the
dominant molecular effects causing the disease.
Third, the fact that a disease is caused by a malfunc-
tion of a particular protein makes it easier to find a
treatment that will reverse the effect. Because the
target protein is known, the effects caused by mis-
sense mutations will be pinpointed by in silico model-
ing and small molecules bound to the target protein
might be able to reverse the effect. Fourth, the fact
that the disease is caused by a single mutation in a
particular protein allows experiments be designed
and carried out to directly test in silico generated
hypotheses and to follow the effects induced by small
molecule binding.
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Identification of genetic disorders is a crucial step for both
providing an early diagnosis of disease predisposed patients (perso-
nalized diagnostics)16–20 and prescribing the optimal drug (persona-
lized medicine).21 22 However, identifying disease-causing genetic
differences and distinguishing them from harmless variations is diffi-
cult.23–26 Typically, a disease-causing variant is identified by search-
ing databases of known disease-causing genetic defects or by
machine learning algorithms. However, the success of both of these
approaches depends on the database of known disease-causing
mutations and neither method can classify new mutations. Thus, in
terms of early diagnosis, a new disease-causing DNA variant or a
rare mutation may not be identified by these methods and conse-
quently the patient will not be treated. At the other end of the spec-
trum are methods utilizing first principle approaches. While these
methods should be able to detect new disease-causing mutations,
typically they are not used for screening as they are too time con-
suming. To bridge this gap, approaches based on first principle cal-
culations, but much faster and adjusted to match experimental data,
have been developed.27 Such combined approaches have several
advantages over existing methods and offer several additional out-
comes, which can be extremely useful in personalizing treatment
for patients as: (a) the proposed approaches are not based on a com-
parison, but on first principle approaches, so they can detect defects
potentially causing disease even in cases that are not previously iden-
tified in other patients; (b) they avoid ambiguities associated with
predicting the effects of multiple mutations in terms of their additiv-
ity or compensation (neutralization); and (c) they also provide
details of the molecular mechanisms of the effects, resulting in more
effective personalized treatment.
Currently, most medical research efforts are directed towards
the study and treatment of common diseases, for example
cancer research. Rare diseases are frequently referred to as
‘neglected’ and receive much less attention from the scientific
and pharmaceutical communities. Although these rare disorders
affect few individuals, they can have devastating effects. They
are sometimes severe and affected patients generally cannot
fully participate in society. For patients and their families, pro-
gress in understanding the origin of disease brings hope for the
development of treatment to reduce the burden of the condi-
tion. This work reports the preliminary results of research to
mitigate the effects of X-linked disease-causing mutations by
small molecule binding, an approach used by other groups to
alter the stability of proteins28 29 or protein signaling.30
METHODS
Calculating the changes in folding free energy
One of the main characteristics of each biological macromol-
ecule is its stability, typically referred to as the free energy of
folding/unfolding. There are several distinct approaches for
computing changes in the folding free energy following a single
mutation, ranging from detailed free energy perturbation
methods,31 32 to statistical potentials,33–35 and to methods
based on machine learning,36 37 reviewed in Potapov et al,38
Gromiha et al,39 and Khan and Vihinen.40 Free energy perturb-
ation methods are physically sound but are quite time consum-
ing and thus are unsuitable for evaluating the effects of
hundreds of mutations. Methods based on statistical potentials
are fast, but depend on the training set used to deliver the statis-
tical potentials. On the other hand, machine learning methods
are fast and suitable for large scale predictions, but do not
reveal the reason for the effects, leaving very little information
for analysis of the molecular causes of the disease. Therefore,
we developed our own method suitable for application to a
large number of mutations while at the same time revealing the
atomic details of changes caused by the mutation. The method
is termed the scaled Molecular Mechanics Generalized Born
(sMMGB) approach and is based on the following formula27:
DGðfoldingÞ ¼ GðfoldedÞ GðunfoldedÞ
¼ GðfoldedÞ G0ðunfoldedÞ GxðunfoldedÞ ð1Þ
where G(folded) is the total potential energy of the folded state
and G(unfolded) is the total potential energy of the unfolded
state. The energy, G(unfolded), of the unfolded state, is split into
two terms, G0(unfolded) and Gx(unfolded), as discussed in our
previous work.41–43 Gx(unfolded) is the energy of the unfolded
state of ‘x’ residue segments at the center of the mutation site,
while G0(unfolded) is the energy of the unfolded state of the rest
of protein (figure 1). Under such an assumption, G0(unfolded) is
Figure 1 Approach for modeling
folded and unfolded states.
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identical for WT protein and mutants, cancels out in equation
(2), and therefore does not need to be calculated.
The folding energy change due to a mutation is calculated
with the following equation:
DDGðfolding mutationÞ
¼ DGðfolding WTÞ  DGðfolding mutantÞ
¼ Gðfolded WTÞ Gxðunfolded WTÞ
Gðfolded mutantÞ þGxðunfolded mutantÞ
ð2Þ
where ΔΔG(folding_mutation) represents the folding energy
change due to a mutation, and ΔG(folding_WT) and ΔG(fol-
ding_mutant) are the folding energy of the WT protein and the
mutant, respectively.
It is recognized that the above MMGB method tends to over-
estimate the magnitude of the predicted free energy changes
(compared with the experimental data), mostly because the
entropy is not included, and therefore the predicted ΔΔG may
have to be scaled to match the experimentally determined
changes in the folding free energy. In our previous work27 we
devised an optimization procedure to minimize the root mean
square deviation (RMSD) between the scaled calculated results
and experimental data by scaling the energies via a linear func-
tion with two adjustable parameters. The optimal values of the
adjustable parameters were obtained by minimizing the RMSD
of the predictions against experimental data derived from the
ProTherm website (Thermodynamic Database for Proteins and
Mutants: http://gibk26.bio.kyutech.ac.jp/jouhou/Protherm/
protherm_search.html).44 45 Benchmarking resulted in
RMSD=1.78 kcal/mol and the slope of the linear regression fit
between the experimental data and the calculations was 1.04 on
a set of 1109 mutations.27
Modeling conformational dynamics with molecular
dynamics simulations
Using snapshots of the WT and the corresponding mutant, the
structural dynamics are evaluated via the RMSD. The snapshots
are superimposed on the starting structures as described in our
previous work43 in order to calculate the time averaged RMSD
of the entire structure or selected set of amino acids as:
RMSD ¼
Pn
i¼1
RMSDi
n
ð3Þ
where ‘n’ is the snapshot number, which has an important prop-
erty: it tends asymptotically to a particular value and thus can
be used to assess if the quantity of interest was properly esti-
mated in the particular simulation time window. Once RMSD
reaches a steady value, for both the WT and the mutant, the
simulations are considered to have converged.
Modeling ionization states and the corresponding hydrogen
bond network
The Multi-Conformation Continuum Electrostatics program
(http://134.74.90.158)46–48 is utilized to calculate the pKa’s of
ionizable groups for both the WT and mutant structures and
thus allows the pKa shifts induced by mutation to be calculated
per titratable amino acid:
DpKaiðmutÞ¼ pKaiðWTÞ  pKaiðmutantÞ ð4Þ
where ΔpKai(mut) is the pKa shift of amino acid i due to the
mutation, and pKai(WT) and pKai(mutant) are the pKa values
of amino acid i in the WT protein and the mutant protein,
respectively. As result, one can calculate the following quantity:
SumðDpKaÞ ¼
XN
i
jDpKaiðmutÞj
¼
XN
i
jpKaiðWTÞ  pKaiðmutantÞ
ð5Þ
where Sum(ΔpKa) is the global pKa shift of the whole protein
due to the mutation, which was used to predict the effect of
mutation on the protonation states of the entire protein.
Calculating changes in binding free energy
Binding affinity is another important characteristic of native pro-
teins, as most proteins interact with another partner(s) or form
a dimer of higher level assemblage. In our previous
work,41 42 49 the binding free energy (ΔΔG(binding)) was calcu-
lated as the difference between the total potential energy of the
complex minus the total potential energy of the separated
monomers (figure 2):
DDGðbindingÞ ¼ DGðcomplexÞ  DGðmonomer AÞ
 DGðmonomer Bl ð6Þ
where ΔG(complex) is the potential energy of the complex, and
ΔG(monomer_A) and ΔG(monomer_B) are the potential ener-
gies of monomers ‘A’ and ‘B’, respectively. The energies were
calculated using TINKER software50 utilizing the MMGB
method. Entropy was considered to be the same for the
monomer and the complex and thus cancels out in equation (6),
Figure 2 Approach for calculating
binding.
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and so the change in the potential energy from the unbound to
bound states was considered to be the free energy of binding.
These calculations are done for WT structures and for each
mutant and the difference, which evaluates the effect of the
mutation on the affinity (binding free energy), is calculated as49:
DDDGðmutÞ ¼ DDGðbinding WTÞ
 DDGðbinding mutantÞ ð7Þ
where ΔΔG(binding_WT) is the binding energy of the WT
monomers and ΔΔG(binding_mutant) is the binding energy of
the corresponding mutant.
Virtual screening for small molecules
The structures of the mutants were analyzed to identify surface
cavities close the mutation site. These areas and their associated
structures were used for in silico screening of small molecules to
determine the best candidates and select those where binding
alters the disease-causing effects. We screened a focused
protein–protein interaction inhibitor compounds collection
(taken from ChemBridge: http://www.chembridge.com/index.
php) that was filtered for drug-likeness using the software
FAF-Drugs2.51 The 3D structures of small molecules were gen-
erated using the web server Frog2.52 In silico screening was con-
ducted using the software AutoDock Vina53 54 employing a
stochastic docking algorithm and an empirical scoring function.
The candidate small molecules were ranked according to
binding affinity and the top ranked 500 molecules were consid-
ered. Finally, 10 potential molecules were manually selected
based on expert evaluation of molecule burial and hydrogen
bond formation.
Experimental measurements of the activity of selected
mutants in the presence of small molecules
The enzyme spermine synthase (SMS) mutant, G56S, which
causes Snyder-Robinson syndrome (SRS), was studied to deter-
mine the effect of small molecule binding. The 10 best small
molecule candidates from the virtual screening, being hydropho-
bic, were dissolved in 5% BSA solution so the experiments
could be conducted in water. The G56S mutant protein itself
had little activity compared with WT (1.3% of WT activity)
(figure 3, left panel). However, the addition of 5% BSA
increased G56S mutant activity by 122.2% (a 2.22-fold increase
in activity) (figure 3, right panel).
Activity was measured by following the production of sperm-
ine from spermidine in 100 mM sodium phosphate buffer
(pH 7.5) in the presence of 0.1 mM dcAdoMet as the propyla-
mine donor.55 Reactions were run for 60 min and polyamines
were extracted in 10% trichloroacetic acid. The extracts were
directly injected onto the o-phthalaldehyde postcolumn
ion-exchange HPLC system.56 As no differences were found
when the experiments were repeated, no further independent
measurements were carried out.57 58
RESULTS
In this section, we describe the results of our in silico investiga-
tions of the molecular effects associated with three types of
intellectual disability (SRS, CLIC2-related intellectual disability,
and creatine deficiency syndrome), and then select one particu-
lar missense mutation causing SRS in order to identify small
molecule candidates for binding via virtual screening and test
the effect experimentally.
Snyder-Robinson syndrome
It was shown by Schwartz and co-workers41 59–61 that SRS is
caused by missense mutations in the spermine synthase gene that
encodes a protein (SMS) of 529 amino acids.58 We investigated,
in silico, the molecular effect of three known missense mutations
in SMS (G56S, V132G, and I150T) which have been clinically
identified as causing the condition (figure 4). We utilized the
methods and approaches described above to determine the
effects of these mutations on SMS stability, flexibility, and interac-
tions. Among the findings was the suggestion that the catalytic
residue, Asp276, should be protonated before binding the sub-
strates.41 The pKa calculations revealed an important conse-
quence of the I150T mutation, predicting that it causes pKa
changes in WT SMS involving titratable residues interacting with
the decarboxylated S-adenosylmethionine (MTA) substrate. The
I150T missense mutation was also found to decrease the stability
of the C-terminal domain and to induce structural changes in the
vicinity of the MTA binding site. The other two missense muta-
tions, G56S and V132G, are distant from the active site and do
not perturb its WT properties, but do affect the stability of both
the monomers and the dimer (figure 4). In particular, the G56S
mutation is predicted to greatly reduce dimer affinity and thus
prevent dimer formation. Since dimerization is essential for SMS
Figure 3 Activity of the wild type
(WT) protein and G56S mutant with
and without 5% BSA.
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function, altering WT dimer stability would have a dramatic
effect on SMS function.58
These findings reveal that none of the mutations, including
I150T, is directly involved in catalysis and their effect on SMS
function is indirect. Particularly interesting is the mutation
G56S, which is distant from the binding pocket and was found
to primarily affect the dimerization of SMS, and to have almost
no effect on other SMS properties. The N-terminal domain,
where the mutation site is located, is not active and its role is
simply to facilitate dimer formation. However, if binding of a
small molecule can restore the WT affinity of the dimer, the
G56S mutant will then function similarly to the WT. This will
be explored in the next sections below.
X-linked intellectual disability caused by a CLIC2 gene
defect
The CLIC2 gene codes for a protein, CLIC2, which is believed
to be both a chloride channel and a calcium channel regula-
tor.62–65 Our investigation was based on the recent discovery of
a missense mutation (H101Q) in the CLIC2 gene on Xq28 in a
male with X-linked intellectual disability (XLID) and not found
in healthy individuals.66 At the same time, numerous nsSNPs
(non-synonymous SNPs) have been reported in the CLIC2 gene
in healthy individuals, indicating that the CLIC2 protein can tol-
erate amino acid substitutions and still be fully functional
(figure 5). Our modeling predicted that H101Q, in contrast
with other nsSNPs, (a) rigidifies the joint loop which is import-
ant for the normal functioning of CLIC2, (b) stabilises the
overall 3D structure of CLIC2 and thus reduces the possibility
of large conformational change expected to occur when CLIC2
moves from a soluble to a membrane form, and (c) removes the
positively charged residue, H101, which may be important for
the membrane association of CLIC2 and interaction with ryano-
dine receptors. The results of in silico modeling, in conjunction
with the polymorphism analysis, suggest that p.H101Q indeed
is a disease-causing mutation, the first suggested in the CLIC
family,66 as recently confirmed experimentally.67
Very little is known about the function(s) of CLIC2, but two
critical requirements are known: it has to interact with the ryano-
dine receptor in order to regulate calcium transport and it must
be inserted into the membrane bilayer to function as a chloride
channel. However, the molecular details of these reactions are
currently not available. Our modeling of the CLIC2–ryanodine
receptor indicates that H101 is very close to the interface of the
complex and is situated in a positive potential. Replacement of
positively charged His with polar but uncharged Gln is expected
to dramatically change CLIC–ryanodine receptor interactions.
However, WT binding affinity, in principle, can be rescued by
small molecule binding at the interface of the CLIC2–ryanodine
receptor. The other event, insertion into the lipid membrane and
functioning as a chloride channel, is much more difficult to
model. Initial investigations suggest that this would require sig-
nificant conformational change associated with the N-terminal
domain of CLIC2 and formation of a dimer/trimer within the
membrane. Such a large conformational change would require
rearrangement of the N-terminal domain of CLIC2, which in
turn would require that the ‘joint loop’ (figure 5) be able to
adopt different conformations as well. The H101Q mutation is
predicted to rigidify the loop, which would therefore need to be
destabilized in order to rescue WT flexibility.
Creatine deficiency syndrome
The intellectual disability associated with creatine deficiency syn-
drome is caused by malfunctioning of a protein coded by the
SLC6A8 gene. The structure of the protein is not available
experimentally and so for the purposes of this work, it was built
in silico by homology modeling. The mutations were mapped
onto the model but none were found to be or be close to the
active site residue. Many of the mutation sites are exposed to
the water phase. The results of in silico modeling of the changes
in the folding free energy indicate that some mutations make
the protein more, while others make it less stable by a significant
amount of energy (figure 6). Previous investigations have shown
that over-stabilization and destabilization are equally disadvanta-
geous for WT function. Two types of missense mutations are
known for this protein: disease-causing missense mutations,
c.1361C>T (p.P544L), c.259G>A (p.G87R), c.1169C>T
(p.P390L), c.1011C>G (p.C337W), c.1161C>T (p.P554L),
c.1141G>C (p.G381R), c.1271G>A (p.G424D), c.1067G>T
(p.G356V), c.1171C>T (p.R391W), c.1145C>T (p.P382L),
G132V, C491W, and c.757G>C (p.G253R), which are located
in the highly conserved sequence regions, except for
c.1210G>C (p.A404P); and five harmless missense mutations,
c.11A>G (p.K4R), c.76G>A (p.G26R), c.544G>A
(p.V182M), c.1678A>G (p.M560V), and c.1185G>A (p.V629I),
which are located in sequence regions which are not highly con-
served. The results of the energy calculations were able to
predict all of the harmless mutations (region 2 in figure 6) and
most of the disease-causing mutations (regions 1 and 3 in
figure 6). These energy regions in figure 6 were assigned using a
Figure 5 The 3D structure of CLIC2 protein. The mutation sites are
indicated with colored balls.
Figure 4 The 3D structure of SMS. The mutations sites are indicated
with colored balls.
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threshold of 5 kcal/mol, which causes both stabilization and
destabilization of the protein. This threshold was selected to
include in region 2 all harmless mutations, but it is obvious that
such a value is protein specific and cannot be predicted without
experimental data. It can be seen that disease-causing mutations
either strongly destabilize the protein (region 1) or in some
cases (region 3) make it more stable. In both cases, this results
in a significant deviation of the WT characteristics of the
protein. Some of the known disease-causing mutations are pre-
dicted to cause very small changes in the folding free energy
(region 2), of the same order of magnitude as the harmless
mutations. Therefore, the disease-causing effect associated with
these mutations does not impact the stability, but perhaps some-
thing related to their position in the 3D structure of the protein
inserted into the membrane (note that in this work the mem-
brane was not included in the modeling). Further investigations
are needed to elucidate the pathogenic effect of the disease-
causing mutations listed in region 2.
A significant fraction of disease-causing mutations are located
the loops connecting the SLC6A8 helices and are accessible from
the water phase. Therefore, restoring the WTstability of SLC6A8
is plausible by targeting the mutation sites with small molecules,
the binding of which would reduce the effects shown in figure 6.
Virtual screening for small molecules for the G56S SMS
mutant
To illustrate the possibility of neutralizing disease-causing
effects, we choose a particular mutant protein, the G56S SMS
mutant causing SRS, and conducted virtual screening to identify
small drug-like molecules capable of stabilizing the dimer. Our
hypothesis is that such stabilization will increase the activity of
the mutant G56S SMS. To this end we targeted in silico a large
druggable zone that was identified on the mutant dimer (shown
in figure 7). The pocket is situated between the interfaces of
N-terminal domains of SMS and is accessible from the water
phase. Binding a small molecule into the pocket would fill the
gap between the interfaces and remove the water, and thus
could increase dimer affinity. For this purpose we analyzed 10
docking poses per molecule for the top ranked 500 molecules,
looking for shape complementarity, hydrogen bonds, and hydro-
phobic interactions between the mutant dimer and the docked
ligands. We subjected the 10 top compounds to in vitro essays
(see next paragraph) and identified three molecules which
experimentally increased the activity of the mutant G56S SMS.
Figure 7 shows the best poses of the three molecules docked on
the dimer. As can be seen, the three molecules anchor in the
same cavity close to the mutation site. Several ‘hot spot’ residues
are involved in the predicted protein–ligand interactions. The
binding mode of molecule 5790328 suggests: (a) hydrogen
bond interactions with H81 from the opposite chain (indicated
as H462 in figure 7) (the protonated ND1) and P3 (P16 in the
SMS sequence) (the backbone CO); (b) aromatic interactions
with Y79 from the opposite chain (indicated as Y460 in
figure 7) and Y76 (Y91 in the SMS sequence); and (c) hydro-
phobic contacts with the V2 (V15 in the SMS sequence) side
chain. The same polar and hydrophobic interactions are sug-
gested for molecule 7754012 (aromatic contacts with Y76 (Y91
in the SMS sequence)). The third molecule 9129729 is found to
have two hydrogen bonds with D59 from the opposite chain
(indicated as D440 in figure 7) (the backbone CO and the side
chain). Again V2 (V15 in the SMS sequence) and P3 (P16 in the
SMS sequence) are suggested to be involved in hydrophobic
interactions with 9129729. The three predicted binding modes
strongly support the identified potential druggable pocket,
which is further validated experimentally in the next paragraph.
Experimental investigation of the effect of small molecules
on the activity of the G56S SMS mutant
The 10 top small molecule candidates identified by virtual
screening above were purchased and experiments carried out to
Figure 6 Predicted folding free energy changes for the SLC6A8 protein for each of 17 mutations.
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determine their effect on G56S SMS mutant activity (see the
Methods section for details). The results of experimental investi-
gations are very promising, as can be seen in figure 7. The verti-
cal axis of the graph shows activity normalized to 100% for the
G56S SMS mutant without the binding of small molecules (left-
most bar in figure 8). The horizontal axis indicates the small
molecule ID number. It can be seen that some of the small
molecules increased the activity of the G56S SMS mutant by
more than 30% (9129729, 7754012, and 5790327). Although
none of the small molecules were able to completely restore the
WT activity of SMS, the trend is clear: activity is increased by
small molecules present in the solution. Further work is under-
way on larger set of small molecules to investigate their physical
binding to SMS.
CONCLUSIONS
Three mutations implicated in XLID were studied in this work
based on the 3D structure of the corresponding protein. It was
shown that none of the mutations in this particular set affect the
active site or directly participate in the corresponding biochem-
ical reaction. Some of the mutations were predicted to decrease
WT stability and the binding affinity of the corresponding
protein, while others were calculated to increase stability. This
indicates that any substantial deviation away from WT character-
istics can cause disease, but there is no clear metric to determine
how large the deviation needs to be. In some cases, a change in
stability or binding affinity caused by a kcal/mol can have a
significant effect; in other cases, it may have no impact on the
function of the corresponding protein. Instead of addressing
this difficult question, one can ask ‘can we restore the WT char-
acteristics by binding small molecules to the mutant?’ Indeed it
should be possible, since almost all mutation sites studied in this
work are accessible from the water phase. We demonstrate for a
particular case that the disease-causing effect can be reduced by
small molecule binding to the mutant. The results of in silico
modeling were experimentally tested and it was shown that
some small molecules indeed increase the activity of the mal-
functioning protein by more than 30%.
The presented approach is dependent on the existence of a
3D structure of the corresponding protein, either experimen-
tally determined or capable of being modeled accurately. In
some cases, particularly those involving large scaffolding or
membrane proteins, the 3D structure may not be available, and
thus the proposed methodology will not be applicable. Without
a 3D structure, the free energy calculations and structural ana-
lysis of the effects caused by the mutations cannot be carried
out, nor can structure-based virtual screening for small molecule
candidates. Alternative bioinformatics approaches should be
developed and tested.
The proposed approach assumes that the disease-causing
effects can be reversed through small molecule binding. Indeed,
for the G56S SMS mutant it was experimentally shown that
some small molecules increase G56S activity. The validity of this
methodology has also been confirmed by other researchers.28–30
Figure 7 Best poses of the three active molecules docked on the mutant G65S dimer. Residues are numbered according to the SMS sequence, not
according to the 3C6K PDB structure (see text).
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However, in many other cases the disease-causing mutation may
truncate the mutation resulting in a truncated protein, which
includes instances of proteins lacking the active site residues.
Even where the mutant is a full length protein, the mutation can
have a devastating effect on the WT properties of the protein,
for example, a hydrophilic mutation in the hydrophobic core of
the protein. Obviously such cases cannot be repaired by small
molecule binding.
In terms of small molecule binding, binding requires the exist-
ence of an appropriate binding cavity or a patch of residues.
The binding epitope in this work was sought close to the muta-
tion site, but, in principle, this should not be a limitation. Due
to the cooperation of intra- and inter-molecular interactions, it
can be speculated that even binding away from the mutation site
could introduce the compensating effect. However, finding a
small molecule which binds with high affinity to the target
mutant and at the same time affects the mutant’s properties in
the desired fashion is a difficult goal and may not be achievable
in all cases.
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